Sectoral / Thematic · Equity

ITI Pharma & Healthcare Fund

ITI Asset Management Limited

Benchmark

NIFTY Healthcare TRI

Riskometer

Very High

Size

₹260 cr

Allotted

Not on record

Holdings as of

30 Sep 2026

ITI Pharma & Healthcare Fund is a sectoral / thematic fund of ITI Asset Management Limited with ₹260 cr under management. It is ahead of its benchmark (NIFTY Healthcare TRI) in 0 of 2 periods. Its direct plan charges 0.89% a year. Animesh Singh has managed it for 0.4 years.

Has ITI Pharma & Healthcare Fund beaten its benchmark?

Ahead of its benchmark, NIFTY Healthcare TRI, in 0 of 2 periods in AMFI's figures; +6.91% over the last year against +8.08%.

Period returns

Direct Plan, growth · 3y and longer a year

Period	Fund	Nifty 500 TRI	Ahead
1 month	−5.53%	−3.60%	—
3 months	−3.07%	−5.03%	—
6 months	+11.69%	−1.83%	—
1 year	+6.45%	−4.06%	+10.51 pts
3 years	+17.62%	+9.27%	+8.35 pts
5 years	—	+8.00%	—
10 years	—	+12.69%	—
Since start from 11 Nov 2021	+13.67%	—	—

Valarth price history to 14 Oct 2026 · the index is the one the fund is nearest; — not on record

Official figures

AMFI performance feed, 13 Oct 2026

Ahead of its benchmark (NIFTY Healthcare TRI) in 0 of 2 periods.

Period	Direct	Regular	Benchmark	Ahead	Rank
1y	+6.91%	+5.00%	+8.08%	−1.17	🔒
3y	+17.99%	+15.82%	+18.79%	−0.80	🔒
5y	—	—	—	—	—
10y	—	—	—	—	—

Ahead in points a year · its rank among Sectoral / Thematic funds, and how steady the lead is, in the app

Value of 100, month-end

Nov 2021 to 14 Oct 2026

Fund 190Nifty 500 TRI 158

₹100 put in at the start of Nov 2021 would be ₹190 on 14 Oct 2026, against ₹158 in the Nifty 500 TRI.

Risk, falls and every year

🔒 Pro

Its worst fall and how long it took to recover, three-year stretches, Sharpe, beta and capture ratios, calendar years beside the index, and money in and out: in the app.

See them in the app →

What does ITI Pharma & Healthcare Fund cost?

0.89% a year on the direct plan, 2.59% on the regular plan; 17 of 174 funds in its category charge less.

Direct plan

0.89% a year

Category median 1.22%

Regular plan

2.59% a year

Category median 2.38%

Gap

1.70 points

for the same holdings

17 of 174 funds in its category charge less on the direct plan.

Expense report, Oct 2026 · Equity Scheme - Sectoral/ Thematic

What the regular plan costs you over time

🔒 Pro

The same money left for years in the direct and the regular plan, side by side, and what the commission takes: in the app.

Who manages ITI Pharma & Healthcare Fund?

Animesh Singh, since 8 May 2026; Nilay Dalal, since 8 May 2026.

Animesh Singh

0.4 years

since 8 May 2026

Nilay Dalal

0.4 years

since 8 May 2026

Benchmark as filedNifty Healthcare Total Return Index

Exit load

If redeemed/Switched out on or before 3 Months from the date of allotment; Exit Load is 0.50% Exit Load after completion of 3 months - NIL

From 6 Scheme Summary Documents filed with NSE, first on 29 Apr 2026; as on 29 Sep 2026

What does ITI Pharma & Healthcare Fund hold?

38 holdings as of 30 Sep 2026; the ten largest are 57.0% of the fund, the largest Sun Pharmaceutical Industries Limited at 12.0%.

Mix

Holdings as of 30 Sep 2026

Equity99.3%Debt0.0%Cash0.7%Other0.0%

Holdings

37 shares

Top ten

57.0%

of the fund

Effective holdings

20.7

spread, as if equal-weighted

Matched to our table

100%

of the equity

Five largest

% of fund

Sun Pharmaceutical Industries Limited12.0%

Divi's Laboratories Limited9.51%

Apollo Hospitals Enterprise Limited5.45%

Dr. Reddy's Laboratories Limited4.78%

Torrent Pharmaceuticals Limited4.78%

Five largest industries

% of fund

Pharmaceuticals & Biotechnology75.3%

Healthcare Services21.0%

Healthcare Equipment & Supplies1.50%

Consumer Durables1.20%

Chemicals & Petrochemicals0.90%

By company size

% of equity · SEBI size lists

Large Cap36.1%Mid Cap40.7%Small Cap23.1%

How does ITI Pharma & Healthcare Fund score against its category?

Seven scores against funds of its kind, and the warning signs it trips.

Scorecard

🔒 Pro

Seven scores, each out of 5, against funds in its category, with the reasons, and the warning signs it trips: in the app.

Open scorecard in the app →

Are the companies inside any good?

The holdings by valuation, forensic risk, business quality and balance sheet, weighted by their share of the fund.

The companies inside

🔒 Pro

The holdings weighted by their share of the fund: P/E and ROE, forensic risk levels, Valarth's valuation view, quality, moats, balance sheets and who owns them: in the app.

How is ITI Pharma & Healthcare Fund run?

Turnover, what it bought and sold, its cash and its record in new listings, from its monthly holdings files.

How it is run

🔒 Pro

Turnover, what it bought and sold and when, how long it holds, size drift, cash and its record in new listings, from up to two years of monthly holdings files: in the app.

Which funds hold much the same?

The index it is nearest and the funds whose holdings overlap most.

not an index tracker

Nearest to the Nifty Midcap 150: 89% of it differs from the index (an active fund is usually above 60%).

Active share 89.2%60%

Funds that hold much the same

% of holdings in common

Mirae Asset Nifty 500 Healthcare ETF76.3% the same

31 shared holdings

Motilal OswalBSE Healthcare ETF73.0% the same

35 shared holdings

Bandhan BSE Healthcare Index Fund73.0% the same

35 shared holdings

How much is in its sponsor's own group?

Holdings in companies of the fund house's sponsor group, beside the index.

Related-party exposure

🔒 Pro

How much of the fund is in companies of its sponsor's own group, beside what the index holds of them: in the app.

Questions people ask

Who manages ITI Pharma & Healthcare Fund?

Animesh Singh (manager) since 8 May 2026; Nilay Dalal (manager) since 8 May 2026.

What is the expense ratio of ITI Pharma & Healthcare Fund?

0.89% a year on the direct plan and 2.59% on the regular plan (expense report, Oct 2026).

How has ITI Pharma & Healthcare Fund done?

Its direct plan returned +17.99% a year over 3 years against +18.79% for its benchmark, NIFTY Healthcare TRI, as of 13 Oct 2026.